A detailed history of Pfm Health Sciences, LP transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Pfm Health Sciences, LP holds 3,241,074 shares of HOWL stock, worth $7.32 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
3,241,074
Previous 3,006,734 7.79%
Holding current value
$7.32 Million
Previous $19.5 Million 59.41%
% of portfolio
0.41%
Previous 0.96%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.34 - $6.75 $548,355 - $1.58 Million
234,340 Added 7.79%
3,241,074 $7.91 Million
Q1 2024

May 14, 2024

SELL
$3.92 - $7.91 $1.81 Million - $3.65 Million
-461,443 Reduced 13.31%
3,006,734 $19.5 Million
Q4 2023

Feb 14, 2024

BUY
$1.78 - $4.15 $1.62 Million - $3.78 Million
909,895 Added 35.57%
3,468,177 $13.4 Million
Q3 2023

Nov 14, 2023

BUY
$2.0 - $3.82 $508,782 - $971,773
254,391 Added 11.04%
2,558,282 $5.47 Million
Q2 2023

Aug 14, 2023

BUY
$2.31 - $3.65 $200,210 - $316,349
86,671 Added 3.91%
2,303,891 $7.03 Million
Q1 2023

May 15, 2023

BUY
$1.98 - $4.3 $1.83 Million - $3.97 Million
923,927 Added 71.44%
2,217,220 $5.76 Million
Q4 2022

Feb 14, 2023

SELL
$1.53 - $4.73 $2.33 Million - $7.2 Million
-1,522,361 Reduced 54.07%
1,293,293 $2.65 Million
Q3 2022

Nov 14, 2022

BUY
$4.14 - $7.42 $4.49 Million - $8.05 Million
1,084,931 Added 62.69%
2,815,654 $12.7 Million
Q2 2022

Aug 15, 2022

BUY
$3.43 - $5.98 $3.93 Million - $6.85 Million
1,145,396 Added 195.68%
1,730,723 $7.08 Million
Q1 2022

May 16, 2022

BUY
$3.71 - $12.22 $687,563 - $2.26 Million
185,327 Added 46.33%
585,327 $2.58 Million
Q2 2021

Aug 16, 2021

BUY
$11.6 - $17.44 $4.64 Million - $6.98 Million
400,000 New
400,000 $6.98 Million

Others Institutions Holding HOWL

About Werewolf Therapeutics, Inc.


  • Ticker HOWL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,529,400
  • Market Cap $66.7M
  • Description
  • Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...
More about HOWL
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.